Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xilio TherapeuticsXLO +1.05%32 EV-to-EBIT is 2.06 as of Jul. 26, 2026, which is 222% above its 10-year median of 0.64. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 378 Biotechnology companies, Xilio Therapeutics ranks better than 70.9% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Xilio Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-95.06 Mil.
Xilio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics EV-to-EBIT Related Terms
Xilio Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Xilio Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xilio Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xilio Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's EV-to-EBIT falls into.
Xilio Therapeutics's current Enterprise Value is $-86.89 Mil.
Xilio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics (XLO) has a EV-to-EBIT of 2.06 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xilio Therapeutics and its competitors. This is 222% above median its historical median of 0.64. According to the industry distribution chart, Xilio Therapeutics ranks #110 out of 378 companies in the Biotechnology industry, placing it in the top 29.1%.
Is Xilio Therapeutics' EV-to-EBIT too high?
Xilio Therapeutics' current EV-to-EBIT of 2.06 is 222% above median its 10-year median of 0.64. The Biotechnology industry median EV-to-EBIT is 12.78. Xilio Therapeutics' value of 2.06 is 83.9% below this industry median. Based on the distribution chart, Xilio Therapeutics ranks #110 out of 378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' EV-to-EBIT compare to FLNA and BSEM?
According to the Biotechnology industry distribution chart, Xilio Therapeutics ranks #110 out of 378 companies for EV-to-EBIT. This puts Xilio Therapeutics in the upper half of its industry. The industry median EV-to-EBIT is 12.78. Xilio Therapeutics' value of 2.06 is 83.9% below this benchmark. While the company's 10-year median is 0.64 vs. the industry median of 12.78, Xilio Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xilio Therapeutics's current EV-to-EBIT of 2.06 is 83.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xilio Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xilio Therapeutics's current EV-to-EBIT is 2.06, which is 222% above median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current EV-to-EBIT of 2.06. The current EV-to-EBIT is 2.06, which is 222% above median its 10-year median of 0.64 and 83.9% below the Biotechnology industry median of 12.78. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current EV-to-EBIT is 2.06 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score
Get the complete analysis for XLO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XLO has been successfully added to your 
